Blake Insomnia Therapeutics, Inc. announced that on May 15, 2019, the board of directors of the company voted to increase the size of the Board from one director to two directors, and to recommend that the shareholders of the Company elect Daniel Blum to serve as a member of the Board. Further, on May 15, 2019, the majority shareholder of the company (the “Shareholder”) elected Daniel Blum to serve on the Board of the company. Additionally, on May 15, 2019, Daniel Cattlin, the company's President, Chief Executive Officer, Treasurer, and a member of the Board, submitted to the company his resignation letter pursuant to which he resigned from his positions as President, Chief Executive Officer, Treasurer, and member of the Board.

Mr. Cattlin's resignation was not a result of any disagreements relating to the company's operations, policies or practices. Also, on May 15, 2019, the Board accepted the resignation of Daniel Cattlin and appointed Daniel Blum to serve as the President, Chief Executive Officer, Secretary, and Treasurer of the company.